Last 12 months
Inside the activity.
0 purchase rows · 10 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2018 Filed Jan 3, 2018 14:13 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Tax withholdingCommon Stock | 459 | $4.91 | $2,253.69 |
DisclosureSEC source: 0001127602-18-000308 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,090 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 14:11 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Tax withholdingCommon Stock | 838 | $4.91 | $4,114.58 |
DisclosureSEC source: 0001127602-18-000306 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,868 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 14:04 UTC |
Sheridan William PSenior VP - CMO
|
Tax withholdingCommon Stock | 1,169 | $4.91 | $5,739.79 |
DisclosureSEC source: 0001127602-18-000303 · form4.xml · nonDerivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,686 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 14:02 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Tax withholdingCommon Stock | 852 | $4.91 | $4,183.32 |
DisclosureSEC source: 0001127602-18-000299 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,362 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 13:59 UTC |
Stonehouse Jon PDirector · President & CEO
|
Tax withholdingCommon Stock | 2,716 | $4.91 | $13,335.56 |
DisclosureSEC source: 0001127602-18-000295 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,951 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:16 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035406 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:15 UTC |
Powell LynneSenior VP - CCO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035403 · form4.xml · derivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:13 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035401 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:10 UTC |
Sheridan William PSenior VP - CMO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035399 · form4.xml · derivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:06 UTC |
Stonehouse Jon PDirector · President & CEO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035395 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:09 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035397 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 20:53 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 3,690 | $5.08 | $18,745.20 |
DisclosureSEC source: 0001127602-17-033783 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,130 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 20:50 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 1,968 | $5.08 | $9,997.44 |
DisclosureSEC source: 0001127602-17-033780 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,135 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 21:09 UTC |
Sheridan William PSenior VP - CMO
|
SaleCommon Stock | 64,310 | $4.72 | $303,543.20 |
DisclosureSEC source: 0001127602-17-032183 · form4.xml · nonDerivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,855 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person and represents approximately 6 percent of the reporting person's pre-sale vested and unvested holdings. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.65 to $4.78. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 14:07 UTC |
Cohen Fred EDirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 54,250 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001127602-17-027802 · form4.xml · derivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,250 shares Expires 2017-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This transaction was made due to the upcoming expiration of the option. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 14:07 UTC |
Cohen Fred EDirector
|
SaleCommon Stock | 54,250 | $5.42 | $294,035.00 |
DisclosureSEC source: 0001127602-17-027802 · form4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,410 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.40 to $5.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 14:07 UTC |
Cohen Fred EDirector
|
Exercise / conversionCommon Stock | 54,250 | $4.27 | $231,647.50 |
DisclosureSEC source: 0001127602-17-027802 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 15:29 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 3,676 | $5.10 | $18,747.60 |
DisclosureSEC source: 0001127602-17-026880 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,440 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 15:27 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 1,960 | $5.10 | $9,996.00 |
DisclosureSEC source: 0001127602-17-026878 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,167 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:49 UTC |
Powell LynneSenior VP - CCO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001127602-17-026944 · form4.xml · derivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2025-01-26 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded to the reporting person in January 2015 has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:40 UTC |
Sheridan William PSenior VP - CMO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 33,900 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-17-026940 · form4.xml · derivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,900 Underlying: Common Stock · 33,900 shares Expires 2024-12-22 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:43 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 18,600 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-17-026942 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2024-12-22 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:33 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-17-026936 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2024-12-22 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:37 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-17-026938 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2024-12-22 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:26 UTC |
Stonehouse Jon PDirector · President & CEO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 40,710 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001127602-17-026934 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,710 Underlying: Common Stock · 40,710 shares Expires 2025-01-01 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded to the reporting person in January 2015 has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:04 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 1,941 | $5.15 | $9,996.15 |
DisclosureSEC source: 0001127602-17-020306 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,764 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:01 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 1,941 | $5.15 | $9,996.15 |
DisclosureSEC source: 0001127602-17-020296 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,207 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 19:59 UTC |
Cohen Fred EDirector
|
GrantCommon Stock | 1,941 | $5.15 | $9,996.15 |
DisclosureSEC source: 0001127602-17-020290 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,410 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:57 UTC |
Patel Sanj KDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019340 · form4.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:53 UTC |
LEE KENNETH B JRDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019338 · form4.xml · derivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:48 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019333 · form4.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:45 UTC |
Hutson Nancy JDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019331 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:42 UTC |
Erck Stanley CDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019329 · form4.xml · derivative · entry 1 Erck Stanley C · CIK 0001342826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:39 UTC |
Cohen Fred EDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019327 · form4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:37 UTC |
ABERCROMBIE GEORGE BDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019325 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:33 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 7,750 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001127602-17-019287 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 7,750 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:33 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Tax withholdingCommon Stock | 6,996 | $5.24 | $36,659.04 |
DisclosureSEC source: 0001127602-17-019287 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,214 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:33 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 7,750 | $4.73 | $36,657.50 |
DisclosureSEC source: 0001127602-17-019287 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 14:40 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-012591 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,805 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 14:40 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 3,250 | $9.20 | $29,900.00 |
DisclosureSEC source: 0001127602-17-012591 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,460 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 14:40 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-17-012591 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · derivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 12,500 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 23,955 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · derivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,055 Underlying: Common Stock · 23,955 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Tax withholdingCommon Stock | 12,308 | $8.80 | $108,310.40 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,460 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 12,500 | $1.42 | $17,750.00 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 23,955 | $3.78 | $90,549.90 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 17:47 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-011528 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,010 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 17:47 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 3,250 | $9.06 | $29,445.00 |
DisclosureSEC source: 0001127602-17-011528 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.02 to $9.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 17:47 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-17-011528 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · derivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,260 Underlying: Common Stock · 6,500 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.